CytomX Therapeutics, Inc.

NasdaqGS:CTMX Stock Report

Mkt Cap: US$183.1m

CytomX Therapeutics Financial Health

How is CytomX Therapeutics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CTMX's short term assets ($200.3M) exceed its short term liabilities ($97.8M).

Long Term Liabilities: CTMX's short term assets ($200.3M) exceed its long term liabilities ($100.2M).

Debt to Equity History and Analysis

Debt Level: CTMX is debt free.

Reducing Debt: CTMX has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTMX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CTMX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies